PegIFN results in higher serological, but not virological, response rates

肝胆速递

Antivir Ther. 2012 Aug 16. doi: 10.3851/IMP2319. [Epub ahead of print]
peginterferon results in higher serological, but not virological, response rates when compared to continuous entecavir.[No authors listed]
Abstract
Background.
HBeAg and HBsAg clearance are associated with an improved prognosis in chronic hepatitis B patients (CHB). These endpoints are more often achieved with a one year course of peginterferon (PEG-IFN) compared with one year of nucleos(t)ide analogue (NA) therapy. However, prolonged NA therapy may result in comparable serological response rates as with PEG-IFN.Methods. We compared serological and virological response rates among HBeAg-positive CHB patients treated with long-term continuous entecavir (ETV) (n=91) for a median of 92 (IQR 50-132) weeks or one year of PEG-IFN (n=266) with comparable follow up.Results. Median follow-up was 92 weeks (IQR 78-198) for patients treated with PEG-IFN, and 92 (IQR 50-132) weeks for patients treated with ETV. Finite PEG-IFN therapy resulted in significantly higher rates of HBeAg seroconversion (adjusted hazard ratio (HR): 3.16,p<0.001) and HBsAg clearance (HR 5.66,p=0.027) when compared to prolonged ETV treatment, whereas ETV resulted in higher rates of HBV DNA undetectability (OR 31.14,p<0.001) also after adjustment for HBV genotype and other relevant baseline factors.
Conclusions. Our study shows that finite PEG-IFN is associated with a higher probability of serological, but not virological, response for HBeAg-positive CHB patients when compared to prolonged ETV, even after correction for baseline differences.

Antiviral疗法2012年8月16日。DOI：10.3851/IMP2319。 [EPUB的提前打印]
聚乙二醇干扰素在高血清学，病毒学，反应率相比，持续恩替卡韦。
[未]
抽象

背景。改善预后的慢性乙型肝炎患者（CHB）与HBeAg和HBsAg清除。这些端点实现了一年的过程中，相对于一年的核苷（酸）类似物（NA）治疗的聚乙二醇干扰素（PEG-IFN）。然而，长期NA治疗，可能会导致可比血清学作为与PEG-IFN.Methods的反应率。我们比较了血清学和病毒学应答率在HBeAg阳性CHB患者长期连续恩替卡韦（ETV）组（n =91）的中位数为92（IQR50-132）周或一年的PEG-IFN（N= 266）相媲美的后续up.Results。中位随访时间为92周（IQR78-198）治疗的患者与PEG-IFN，92（IQR50-132）周恩替卡韦治疗的患者。有限PEG-IFN治疗导致更高的HBeAg血清学转换率（调整后的危险比（HR）：3.16，P <0.001）和HBsAg清除率（HR5.66，P= 0.027）相比，延长ETV治疗，而ETV导致了较高的HBV DNA不可检测率（OR31.14，P <0.001）也调整后HBV基因型和其他相关的基线factors.
Conclusions。我们的研究表明，有限的PEG-IFN的血清学相关的较高的概率，但不病毒学，响应HBeAg阳性CHB患者相比长时间ETV时，即使校正后的基线差异。